Country sequencing, vendor geography, and QP release chains are strategic decisions made, well or poorly, at the US IND stage, long before a company believes it is ready to think globally.
White Paper
Designing a Global IND Strategy Before You Think You Need One
Related Resources
All Resources
post
The Real Cost of Uncertainty: Why On-Again, Off-Again Tariffs Hurt Biotech Supply Chains
Read More
post
Accelerating a Cytotoxic Peptide-Drug Conjugate to IND: A Medicinal Chemist’s Journey to IND with Syner-G BioPharma Group
Read More
post
Navigating Analytical Method Comparability and Equivalency Under ICH Q14: A New Era for Analytical Procedure Lifecycle Management
Read More
case-study
From CDMO to In-House cGMP Manufacturing: Scaling Success in Cell Therapy Technology Transfer
Read More
Let's move from science to success.
Let’s Talk